Q4 FY2022 Earnings August 11, 2022 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financia ...

SECURITIES AND EXCHANGE COMMISSION UNITED STATES Commission file number: 001-15317 ___________________________________________________________________________________________ ResMed Inc. (Exact name of registrant as specified in its charter) ___________________________________________________________________________________________ Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS Employer Identification No.) 9001 Spectrum Center Blvd. San Diego, CA 92123 United States ...

Acquisition of MEDIFOX DAN June 14, 2022 Forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, w ...

Q3 FY2022 Earnings April 28, 2022 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial ...

ResMed Inc. (NYSE:RMD) Q3 2022 Earnings Conference Call April 28, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President and COO Jim Hollingshead - President, Sleep & Respiratory Care business David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants David Low - JPMorgan Gretel Janu - Credit Suisse Lyanne Harrison - Bank of America Saul Hadassin - Barrenjoey Dan Hurren ...

Financial Performance - For the three months ended March 31, 2022, net revenue reached $864.5 million, a 12.4% increase from $768.8 million in the same period of 2021[10] - Net income for the three months ended March 31, 2022, was $179.0 million, compared to a net loss of $78.5 million in the same period of 2021[10] - Basic earnings per share for the three months ended March 31, 2022, was $1.22, compared to a loss of $0.54 per share in the same period of 2021[10] - Comprehensive income for the three months ended March 31, 2022, was $178.0 million, compared to a loss of $111.3 million in the same period of 2021[13] - Net income for the nine months ended March 31, 2022, was $584.376 million, compared to $279.405 million for the same period in 2021, representing a 109% increase[21] - Gross profit for the three months ended March 31, 2022, was $491.2 million for the three months ended March 31, 2022, compared to $447.3 million in the same period of 2021[10] - Gross profit for the nine months ended March 31, 2022 increased to $1,501.8 million, an 11% increase from $1,348.4 million for the same period in 2021[134] Assets and Liabilities - Total current assets increased to $1.7 billion as of March 31, 2022, from $1.6 billion as of June 30, 2021[8] - Total assets as of March 31, 2022, were $4.9 billion, up from $4.7 billion as of June 30, 2021[8] - Total liabilities decreased to $1.6 billion as of March 31, 2022, from $1.8 billion as of June 30, 2021[8] - Total inventories as of March 31, 2022, amounted to $664.9 million, up from $457.0 million as of June 30, 2021, indicating a 45.5% increase[51] - Total debt as of March 31, 2022, was $680.7 million, an increase from $655.4 million on June 30, 2021[69] - Long-term debt increased to $670.0 million as of March 31, 2022, compared to $646.0 million on June 30, 2021[69] Revenue Breakdown - Sleep and Respiratory Care revenue for the nine months ended March 31, 2022, reached $2.37 billion, up 15.8% from $2.04 billion in the prior year[29] - SaaS revenue for the three months ended March 31, 2022, was $101.1 million, reflecting an increase of 7.5% compared to $93.8 million in the same period of 2021[29] - Total Sleep and Respiratory Care revenue for the three months ended March 31, 2022, was $763.4 million, compared to $674.9 million in the same period of 2021, marking a 13.1% increase[29] - The company’s devices revenue for the three months ended March 31, 2022, was $433.1 million, up from $365.7 million in the same period of 2021, representing an 18.4% increase[29] - Net revenue from the Sleep and Respiratory Care business was $763.4 million for the three months ended March 31, 2022, an increase of 13% compared to the same period in 2021[116] - Net revenue from the SaaS business for the nine months ended March 31, 2022, was $297.7 million, reflecting a 7% increase compared to the prior year[131] Expenses - Research and development expenses for the three months ended March 31, 2022, were $66.8 million, an increase from $55.9 million in the same period of 2021[10] - Selling, general, and administrative expenses for the nine months ended March 31, 2022, were $544.5 million, an increase of 11% compared to $488.9 million for the same period in 2021[139] - Research and development expenses for the nine months ended March 31, 2022, increased to $189.3 million, a 14% increase from $165.4 million for the same period in 2021[143] Cash Flow - Cash flows from operating activities for the nine months ended March 31, 2022, were $271.661 million, down from $510.193 million in the prior year[21] - Cash and cash equivalents at the end of the period on March 31, 2022, were $201.769 million, down from $230.635 million at the end of March 31, 2021[21] - The company reported a net cash used in investing activities of $174.677 million for the nine months ended March 31, 2022, compared to $110.390 million in the prior year[21] - The company reported a net cash used in financing activities of $185.862 million for the nine months ended March 31, 2022, compared to $650.596 million in the previous year[21] Shareholder Returns - The company declared a dividend of $0.42 per share for the three months ended March 31, 2022, compared to $0.39 per share in the same period of 2021[10] - The company paid cash dividends of $0.42 per common share totaling $61.4 million during the three months ended March 31, 2022[175] - The company has repurchased a total of 41.8 million shares for an aggregate of $1.6 billion since the inception of its share repurchase programs[176] Market Conditions - The company faced supply chain disruptions due to the COVID-19 pandemic, impacting the availability of raw materials and electronic components[108] - Increased demand for sleep and respiratory care devices was noted following a product recall by a competitor, Philips[109] Other Financial Metrics - The effective income tax rate for the three months ended March 31, 2022, was 20.9%, a significant decrease from 136.0% for the same period in 2021[150] - Non-GAAP net income for the three months ended March 31, 2022, was $193.3 million, compared to $190.4 million for the same period in 2021, indicating stable performance[162] - Non-GAAP diluted earnings per share for the nine months ended March 31, 2022, was $4.30, compared to $3.98 for the same period in 2021, reflecting an increase of 8.0%[162]

ResMed Inc. (NYSE:RMD) Q2 2022 Earnings Conference Call January 27, 2021 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO Brett Sandercock - CFO Rob Douglas - President and COO Jim Hollingshead - President, Sleep & Respiratory Care business David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants Chris Cooper - Goldman Sachs Dan Hurren - MST Marquee Sean Laaman - Morgan Stanley Matthew Mishan - KeyBanc Craig Wong ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (I.R.S. Employer Identification No.) WASHINGTON, DC 20549 ______________________________________________________________________________________________ FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly per ...

40th Annual J.P. Morgan Healthcare Conference Mick Farrell - CEO January 10, 2022 Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures ...

ResMed Inc. (NYSE:RMD) Q1 2022 Earnings Conference Call October 28, 2021 4:30 PM ET Company Participants Amy Wakeham - Vice President, Investor Relations & Corporate Communications Mick Farrell - Chief Executive Officer Brett Sandercock - Chief Financial Officer Rob Douglas - President and Chief Operating Officer Jim Hollingshead - President, Sleep & Respiratory Care business Conference Call Participants Matthew Mishan - KeyBanc Chris Cooper - Goldman Sachs David Low - JPMorgan Suraj Kalia - Oppenheimer Gre ...